🔗 Share this article

This year's Nobel Prize in medical science has been awarded for transformative findings that clarify how the immune system attacks dangerous pathogens while protecting the body's own cells.

A trio of renowned scientists—Japan's Prof. Sakaguchi and US scientists Mary Brunkow and Dr. Ramsdell—share this honor.

Their work uncovered specialized "sentinels" within the defense system that remove rogue defense cells capable of harming the organism.

These findings are now paving the way for innovative treatments for immune disorders and cancer.

The laureates will divide a monetary award valued at 11 million Swedish kronor.

Decisive Findings

"Their research has been decisive for comprehending how the body's defenses functions and why we don't all suffer from serious self-attack conditions," stated the head of the Nobel Committee.

The team's studies explain a core question: In what way does the immune system defend us from countless invaders while leaving our healthy cells unharmed?

The immune system uses immune cells that scan for signs of disease, even viruses and bacteria it has never encountered.

Such defenders employ detectors—known as receptors—that are produced randomly in countless variations.

This gives the defense network the capacity to combat a wide array of invaders, but the randomness of the mechanism inevitably creates white blood cells that can target the body.

Protectors of the Immune System

Scientists previously knew that a portion of these harmful white blood cells were destroyed in the immune organ—the site where immune cells develop.

The latest Nobel Prize honors the discovery of regulatory T-cells—described as the body's "peacekeepers"—which travel through the system to neutralize other defenders that attack the healthy cells.

It is known that this mechanism fails in self-attack conditions such as type-1 diabetes, multiple sclerosis, and rheumatoid arthritis.

The Nobel panel stated, "These findings have laid the foundation for a novel area of investigation and accelerated the creation of new treatments, for example for cancer and immune disorders."

Regarding cancer, T-regs block the body from attacking the tumor, so research are aimed at reducing their numbers.

In self-attack disorders, trials are testing boosting regulatory T-cells so the organism is not being harmed. A comparable approach could also be effective in reducing the chances of transplanted organ rejection.

Innovative Studies

Prof Shimon Sakaguchi, of a Japanese institution, performed tests on rodents that had their immune gland extracted, leading to self-attack conditions.

The researcher showed that injecting immune cells from other animals could prevent the illness—suggesting there was a mechanism for preventing immune cells from harming the host.

Mary Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in a California city, were investigating an inherited immune disorder in rodents and people that led to the identification of a gene vital for the way T-regs function.

"The pioneering work has uncovered how the body's defenses is kept in check by T-reg cells, stopping it from accidentally attacking the healthy cells," said a prominent biological science specialist.

"This work is a remarkable example of how basic physiological study can have far-reaching implications for human health."